Latin American medical cannabis market set to worth $8.5 billion

8 October 2018
cannabis-big

Over the past 24 months, the Latin American cannabis industry has emerged from the shadows to command the attention of the international cannabis community as over ten major markets have legalized medical cannabis.

Legal cannabis sales are expected to be worth $125 million in 2018 but that number is expected to rise to $12.7 billion by 2028.

The figure comes from the recently published The LATAM Cannabis Report, by market intelligence and strategic consultancy firm Prohibition Partners, who have analysed pricing, consumption and patient datasets in the region.

According to the report, the majority of the market value will come from the medical cannabis sector, forecasted to be worth $8.5 billion in 10 years time. In addition, the report predicts that the Latin American market will undercut global cannabis prices, currently retailing at $2 per gram on Uruguay’s regulated marketplace. Offering a low-cost alternative to North American and European markets, licensed producers will look to cultivate in Latin America, creating an international export market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical